• 来稿:陈琳   北京市虹天济神经科学研究院

    Mol Neurobiol. 2007 Feb;35(1):55-84. Review. Erratum in:  Mol Neurobiol. 2008 Feb;37(1):91.

  •  

  •  

  • Neuroprotection against neurodegenerative diseases:  development of a novel hybrid neuroprotective peptide  Colivelin

  •  

  • Chiba T, Nishimoto I, Aiso S,  Matsuoka M.

  • Department of  Anatomy and Pharmacology, KEIO University School of Medicine, Shinjuku-ku,  Tokyo, Japan.  chibat@sc.itc.keio.ac.jp

  •  

  • Neuronal death is directly implicated in the pathogenesis  of neurodegenerative diseases (NDDs). NDDs cannot be cured because the  mechanisms underlying neuronal death are too complicated to be therapeutically  suppressed. Neuroprotective factors, such as neurotrophins, certain growth  factors, neurotrophic cytokines, and short neuroprotective peptides, support  neuronal survival in both physiological and pathological conditions, suggesting  that these factors may be good drug candidates for NDDs. We recently generated a  novel neuroprotective peptide named Colivelin by attaching activity-dependent  neurotrophic factor (ADNF) to the N-terminus of a potent Humanin derivative,  AGA-(C8R) HNG17. HN was originally identified from an Alzheimer's disease (AD)  brain as an endogenous neuroprotective peptide that suppresses ADrelevant  toxicity. Colivelin protects neurons from death relevant to NDDs by activating  two independent prosurvival signals: an ADNF-mediated Ca2+/calmodulin-dependent  protein kinase IV pathway and an HN-mediated STAT3 pathway. The neuroprotective  effect of Colivelin provides novel insights into therapy for  NDDs.


多发性硬化症及其他神经退行性疾病中的神经退行性病变和神经保护
姜黄素的神经保护性作用

Previous:

Next:

对退行性神经疾病的神经保护:新型神经保护性混合肽Colivelin的研制